Organ |
liver |
Age classes |
adult |
Gender |
F |
phase I metabolism > CYP content > microsomes |
1350 pmol CYP/mg protein RATIO: 4
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP3A4 > testosterone 6β-hydroxylation > microsomes |
5000 pmol/min/mg protein RATIO: 0.9
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2E1 > ethoxycoumarin O-deethylation > microsomes |
8956 pmol/min/mg protein RATIO: 25.1
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2E1 > chlorzoxazone 6-hydroxylation > microsomes |
3027 pmol/min/mg protein RATIO: 1.8
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2D6 > dextromethorphan O-demethylation > microsomes |
802 pmol/min/mg protein RATIO: 6.3
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2C19 > S-mephenytoin 4-hydroxylation > microsomes |
3 pmol/min/mg protein RATIO: 0.2
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP2A6 > coumarin 7-hydroxylation > microsomes |
1750 pmol/min/mg protein RATIO: 1
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|
phase I metabolism > CYP1A2 > phenacetin O-deethylation > microsomes |
441 pmol/min/mg protein RATIO: 1.8
|
SanverTech., 1999 - Product characterisation form of In Vitro Technologies, SanverTech, 1999.
|